• BIA Blog

In2scienceUK, promoting diversity and inclusion within STEM

In2scienceUK is a charity that empowers young people from low-income backgrounds to reach their potential and progress to careers in Science, Technology, Engineering and Mathematics (STEM)

Madonna, mass consumption and microbes

In his guest blog, Dr Edward Green, CEO at NCIMB shares the potential of microbes to achieve some of the UN's Sustainable Development Goals and address global challenges.

CEO Update - 22 May 2023

On Thursday I will be attending the bi-annual UK Life Science Council, the set piece meeting of the UK life science industry with the UK government. Thanks to months-long backroom work, by the BIA team and civil servants, I think the scene is set for a productive discussion on the Scale Up finance agenda, what we need to do to get clinical trials going again in the UK and how we can support the development of a skilled workforce in life science.

CEO Update - 15 May 2023

Today we launched the #BIGIMPACT campaign to encourage next-generation digital talent to start a career in the biotech industry. The campaign addresses an urgent need for data, machine learning and AI skills and shines a spotlight on new career pathways that are possible in biotech.

UK biotech shows progress on diversity - and has more to do

Industry survey on Diversity, Equity and Inclusion (DEI) can guide efforts to expand the talent pool and investment in UK biotech, says Alina O’Keeffe, Head of Marketing and Membership Communications at the BIA.

CEO Update - 9 May 2023

It was heartening last week to see positive results from Lilly's trial of donanemab for Alzheimer’s disease. It is an important step and, although there is a long way to go before products like these become routine in clinical practice in the UK, it is great to see positive news. An experimental Alzheimer's drug slowed cognitive decline by 35% in a late-stage trial with 1,182 people, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Read on for VPAS, local elections, FCA reforms and a new approach to importing into Great Britain.

Prioritising patient access

Next-generation sequencing and many other tools provide tremendous new insights into human biology. Emerging techniques, such as CRISPR technology and cell and gene therapies are providing new opportunities to treat and possibly even cure some of the most intractable diseases.

New Act opens doors for modern biotechnology in England

The Genetic Technologies (Precision Breeding) Act was passed into law in England in March 2023 to enable the development and marketing of gene-edited crops and animals in England, allowing us to grow more resilient crops and breed animals that are more resistant to harmful diseases and put those to market.

CEO Update | 2 May 2023

The long-awaited and much-leaked European Commission's pharmaceutical legislation was finally published last week. Most of the new proposals have received a hearty thumbs down from the industry due to concerns that the proposals will limit intellectual property. The EU may be one regulated market but it remains a complex patchwork of national healthcare systems, clinical communities and currencies which do not lend themselves, nor seek to be a homogeneous whole. From a UK perspective, the UK has increased its attractiveness as a market simply by standing still, and I have to admit I didn’t think that it would be direct moves by the EU that would make the case for Brexit. Read more on LIFTS, VPAS and HSBC SVB UK...

Innovation in bioprocessing: How BioProduction by SEKISUI became a leader in global manufacturing

Louise Digby, Commercial Director at BioProduction by SEKISUI, shares challenges, accomplishments and hurdles faced by the company, from building a strong, committed team, to securing investment to expand their cGMP facility.